{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:10:01Z","timestamp":1777918201322,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[1984,10,1]],"date-time":"1984-10-01T00:00:00Z","timestamp":465436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumori"],"published-print":{"date-parts":[[1984,10]]},"abstract":"<jats:p>\n                    Thirty six patients with advanced solid tumors (24 lung: 3 oat-cell, 14 squamous, 7 adenocarcinomas, 3 soft tissue sarcomas, 6 breast carcinomas; 1 seminoma; 2 ovarian adenocarcinomas) entered a phase II study of high-dose ifosfamide (IF) administered in combination with the uroprotective agent sodium 2-mercapto-ethane-sulfonate (Mesna). Fourteen patients had prior treatment; most patients with lung cancer (22\/24) were previously untreated; all had measurable disease. The patients median age was 59 (range 31\u201374). IF was given at 1.8 g\/m\n                    <jats:sup>2<\/jats:sup>\n                    days 1\u20135 q 4 weeks. Mesna was given after each IF injection at 0, 4 and 8 h randomly, either i.v. (0.36 g\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) or orally (0.72 g\/m\n                    <jats:sup>2<\/jats:sup>\n                    ). Twenty-four patients had \u2265 3 courses of therapy, 9 had 2 courses, and 3 had only 1 course; 129 courses were evaluated for toxicity. Mesna was given orally (17 patients, 57 courses) or i.v. (19 patients, 72 courses). The following side-effect were observed: no gross hematuria, microhematuria (14 courses), transitory mild proteinuria (34 courses), leukopenia grade I-II ECOG (26 courses), anemia grade I ECOG (31 courses), 1 case of pancytopenia, alopecia (31 patients), nausea (moderate, 33 courses; severe, 6 courses), vomiting (moderate, 17 courses; severe, 1 course). Five patients showed a partial response (1 oat-cell carcinoma, 2 with squamous lung cancer, 1 with ovarian carcinoma, 1 with breast carcinoma), 14 showed a minor response (2 patients with oat-cell carcinoma, 2 with lung adenocarcinoma, 5 with squamous lung cancer, 1 with seminoma, 1 with sarcoma, 1 with ovarian carcinoma), and 14 showed progression of disease (7 patients with squamous cell lung cancer, 4 with lung adenocarcinoma, 1 with sarcoma, 2 with breast carcinoma). Considering partial plus minor responses, ifosfamide produced some degree of tumor reduction (PR+MR) in 12\/23 (52.1 %) lung cancer patients. The data reported support the conclusions that Mesna can prevent high-dose IF bladder toxicity, that IF is active in advanced solid tumors, including lung cancer, and that the IF + Mesna combination is a generally safe treatment procedure.\n                  <\/jats:p>","DOI":"10.1177\/030089168407000508","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T05:44:48Z","timestamp":1523943888000},"page":"433-437","source":"Crossref","is-referenced-by-count":7,"title":["Phase II Study of Ifosfamide Combined with Mesna Uroprotection in Advanced Non-Small-Cell Lung Carcinoma and Other Solid Tumors"],"prefix":"10.1177","volume":"70","author":[{"given":"Maria Teresa","family":"Nobile","sequence":"first","affiliation":[{"name":"Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Rosso","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvio","family":"Brema","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Cinquegrana","sequence":"additional","affiliation":[{"name":"Divisione di Pneumologia, Ospedali Civili di Genova"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Santi","sequence":"additional","affiliation":[{"name":"Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1984,10]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"1155","article-title":"Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention.","volume":"17","author":"Brock N.","year":"1981","unstructured":"BrockN., PohlJ., StekarJ.: Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur. J. Cancer, 17: 1155\u20131163, 1981.","journal-title":"2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur. J. Cancer"},{"key":"e_1_2_1_3_2","first-page":"659","article-title":"Acrolein, the causative factor of urotoxic side-effect of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.","volume":"29","author":"Brock N.","year":"1979","unstructured":"BrockN., StekarT., PohlJ.: Acrolein, the causative factor of urotoxic side-effect of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforsch\/Drug Res., 29: 659\u2013661, 1979.","journal-title":"Arzneimittelforsch\/Drug Res."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00369371"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(66)90042-9"},{"key":"e_1_2_1_6_2","first-page":"61","article-title":"Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.","volume":"1","author":"Costanzi J.J.","year":"1982","unstructured":"CostanziJ.J., MorganL.R., HokansonJ.: Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung. Semin. Oncol., 9, Suppl. 1: 61\u201365, 1982.","journal-title":"Semin. Oncol., 9, Suppl."},{"key":"e_1_2_1_7_2","first-page":"56","article-title":"Single-dose ifosfamide: efficacy in non-small cell lung cancer.","volume":"1","author":"Harrison E.F.","year":"1982","unstructured":"HarrisonE.F., HawkeJ.E., HunterH.L., CostanziJ.J., MorganL.R., PlotkinD., TuckerW.G., WorralP.M.: Single-dose ifosfamide: efficacy in non-small cell lung cancer. Semin. Oncol., 9: Suppl. 1: 56\u201360, 1982.","journal-title":"Semin. Oncol., 9: Suppl."},{"key":"e_1_2_1_8_2","first-page":"96","article-title":"The anticancer spectrum of ifosfamide.","volume":"1","author":"Hunter H.L.","year":"1982","unstructured":"HunterH.L., HarrisonE.F. The anticancer spectrum of ifosfamide. Semin. Oncol., 9, Suppl. 1: 96\u2013100, 1982.","journal-title":"Semin. Oncol., 9, Suppl."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(77)90237-4"},{"key":"e_1_2_1_10_2","first-page":"71","article-title":"The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung.","volume":"1","author":"Morgan L.R.","year":"1982","unstructured":"MorganL.R., DonleyP.J., HarrisonE.F., HunterH.L.: The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung. Semin. Oncol., 9, Suppl. 1: 71\u201374, 1982.","journal-title":"Semin. Oncol., 9, Suppl."},{"key":"e_1_2_1_11_2","first-page":"66","article-title":"Toxicity of single vs.","volume":"1","author":"Morgan L.R.","year":"1982","unstructured":"MorganL.R., HarrisonE.F., HawkeJ.E., HunterH.L., CostanziJ.J., PlotkinD., TuckerW.G., WorralP.M.: Toxicity of single vs. fractioned-dose ifosfamide in non-small cell lung cancer: a multi-center study. Semin. Oncol., 9, Suppl. 1: 66\u201370, 1982.","journal-title":"fractioned-dose ifosfamide in non-small cell lung cancer: a multi-center study. Semin. Oncol., 9, Suppl."},{"key":"e_1_2_1_12_2","first-page":"1577","article-title":"Cyclophosphamide and urinary bladder toxicity.","volume":"21","author":"Philips F.S.","year":"1961","unstructured":"PhilipsF.S., SternbergS.S., CroninA.P., VidalP.M.: Cyclophosphamide and urinary bladder toxicity. Cancer Res., 21: 1577\u20131589, 1961.","journal-title":"Cancer Res."},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(83)80013-9"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/003591577506800309"},{"key":"e_1_2_1_15_2","first-page":"1889","article-title":"Zur Pathogenese, Klinik und Prophylax der sogenannten cyclophosphamid-zystitis.","volume":"116","author":"Vahlensieck W.","year":"1974","unstructured":"VahlensieckW., Hoefer-JankerH., BruhlP., ScheefW.: Zur Pathogenese, Klinik und Prophylax der sogenannten cyclophosphamid-zystitis. Munch. Med. Wochenschr., 116: 1889\u20131894, 1974.","journal-title":"Munch. Med. Wochenschr."}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089168407000508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089168407000508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:33:26Z","timestamp":1777660406000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030089168407000508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,10]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1984,10]]}},"alternative-id":["10.1177\/030089168407000508"],"URL":"https:\/\/doi.org\/10.1177\/030089168407000508","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,10]]}}}